These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 33792558)

  • 21. Plk1 Inhibition Enhances the Efficacy of BET Epigenetic Reader Blockade in Castration-Resistant Prostate Cancer.
    Mao F; Li J; Luo Q; Wang R; Kong Y; Carlock C; Liu Z; Elzey BD; Liu X
    Mol Cancer Ther; 2018 Jul; 17(7):1554-1565. PubMed ID: 29716963
    [TBL] [Abstract][Full Text] [Related]  

  • 22. m6A Modification Promotes EMT and Metastasis of Castration-Resistant Prostate Cancer by Upregulating NFIB.
    Shu F; Liu H; Chen X; Liu Y; Zhou J; Tang L; Cao W; Yang S; Long Y; Li R; Wang H; Wang H; Jiang G
    Cancer Res; 2024 Jun; 84(12):1947-1962. PubMed ID: 38536119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
    Asangani IA; Dommeti VL; Wang X; Malik R; Cieslik M; Yang R; Escara-Wilke J; Wilder-Romans K; Dhanireddy S; Engelke C; Iyer MK; Jing X; Wu YM; Cao X; Qin ZS; Wang S; Feng FY; Chinnaiyan AM
    Nature; 2014 Jun; 510(7504):278-82. PubMed ID: 24759320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of GRP/GRP-R signaling contributes to castration-resistant prostate cancer progression.
    Qiao J; Grabowska MM; Forestier-Roman IS; Mirosevich J; Case TC; Chung DH; Cates JM; Matusik RJ; Manning HC; Jin R
    Oncotarget; 2016 Sep; 7(38):61955-61969. PubMed ID: 27542219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. siRNA-based approaches for castration-resistant prostate cancer therapy targeting the androgen receptor signaling pathway.
    Yu Y; Papukashvili D; Ren R; Rcheulishvili N; Feng S; Bai W; Zhang H; Xi Y; Lu X; Xing N
    Future Oncol; 2023 Sep; 19(30):2055-2073. PubMed ID: 37823367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.
    Hu R; Lu C; Mostaghel EA; Yegnasubramanian S; Gurel M; Tannahill C; Edwards J; Isaacs WB; Nelson PS; Bluemn E; Plymate SR; Luo J
    Cancer Res; 2012 Jul; 72(14):3457-62. PubMed ID: 22710436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.
    Zheng D; Gui B; Gray KP; Tinay I; Rafiei S; Huang Q; Sweeney CJ; Kibel AS; Jia L
    Oncogene; 2016 Sep; 35(36):4807-15. PubMed ID: 26876202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNA-binding protein DDX3 mediates posttranscriptional regulation of androgen receptor: A mechanism of castration resistance.
    Vellky JE; McSweeney ST; Ricke EA; Ricke WA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28092-28101. PubMed ID: 33106406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer.
    Zhao N; Peacock SO; Lo CH; Heidman LM; Rice MA; Fahrenholtz CD; Greene AM; Magani F; Copello VA; Martinez MJ; Zhang Y; Daaka Y; Lynch CC; Burnstein KL
    Sci Transl Med; 2019 Jun; 11(498):. PubMed ID: 31243151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor: what we know and what we expect in castration-resistant prostate cancer.
    Cai Z; Chen W; Zhang J; Li H
    Int Urol Nephrol; 2018 Oct; 50(10):1753-1764. PubMed ID: 30128923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Androgen receptor co-regulatory networks in castration-resistant prostate cancer.
    Sung YY; Cheung E
    Endocr Relat Cancer; 2014 Feb; 21(1):R1-R11. PubMed ID: 24152433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging Variants of Castration-Resistant Prostate Cancer.
    Vlachostergios PJ; Puca L; Beltran H
    Curr Oncol Rep; 2017 May; 19(5):32. PubMed ID: 28361223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aberrant activation of super enhancer and choline metabolism drive antiandrogen therapy resistance in prostate cancer.
    Wen S; He Y; Wang L; Zhang J; Quan C; Niu Y; Huang H
    Oncogene; 2020 Oct; 39(42):6556-6571. PubMed ID: 32917955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer.
    Chen X; Shao Y; Wei W; Zhu S; Li Y; Chen Y; Li H; Tian H; Sun G; Niu Y; Shang Z
    Cell Death Dis; 2022 Nov; 13(11):927. PubMed ID: 36335093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
    Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
    J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epigenetic Reprogramming with Antisense Oligonucleotides Enhances the Effectiveness of Androgen Receptor Inhibition in Castration-Resistant Prostate Cancer.
    Xiao L; Tien JC; Vo J; Tan M; Parolia A; Zhang Y; Wang L; Qiao Y; Shukla S; Wang X; Zheng H; Su F; Jing X; Luo E; Delekta A; Juckette KM; Xu A; Cao X; Alva AS; Kim Y; MacLeod AR; Chinnaiyan AM
    Cancer Res; 2018 Oct; 78(20):5731-5740. PubMed ID: 30135193
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.
    Gao S; Ye H; Gerrin S; Wang H; Sharma A; Chen S; Patnaik A; Sowalsky AG; Voznesensky O; Han W; Yu Z; Mostaghel EA; Nelson PS; Taplin ME; Balk SP; Cai C
    Clin Cancer Res; 2016 Jul; 22(14):3672-82. PubMed ID: 26936914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.
    Launonen KM; Paakinaho V; Sigismondo G; Malinen M; Sironen R; Hartikainen JM; Laakso H; Visakorpi T; Krijgsveld J; Niskanen EA; Palvimo JJ
    Oncogene; 2021 Jul; 40(27):4567-4579. PubMed ID: 34127815
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer.
    Gritsina G; Gao WQ; Yu J
    Asian J Androl; 2019; 21(3):215-223. PubMed ID: 30950412
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.